US health authority reprimands large pharmaceutical firms after disagreement on drug discounts

Earlier in the week, the US HRSA sent a letter to many of the largest companies in the pharmaceutical industry concerning their approach to the 340B program which aims to ensure that hospitals get drug discounts.

Photo: Mike Segar/Reuters/Ritzau Scanpix

The US Department of Health & Human Services (HHS) is cracking down on many of the largest players in the pharmaceutical industry according to healthcare media Endpoints.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs